Pfizer mulls spin-off or sale of consumer health unit: sources

New York

US drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division that could value the unit at as much as US$14 billion, people familiar with the matter said on Wednesday.

A Pfizer exit from the consumer health business, which includes lip balm Chapstick and painkiller Advil, would be one of its biggest corporate moves since abandoning a US$160 billion deal to buy Irish drugmaker Allergan Inc earlier this year.